Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883261 | 1.00 | USP30 (0.43) | USP30UCHL1ALDH1A1GPR119TSHR | |
| SCHEMBL13179251 | 0.99 | USP30 (0.44) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL14924576 | 0.95 | ALDH1A1 (0.41) | USP30UCHL1ALDH1A1GPR119TSHR | |
| SCHEMBL16904938 | 0.95 | ALDH1A1 (0.41) | USP30UCHL1ALDH1A1GPR119TSHR | |
| SCHEMBL12333035 | 0.95 | USP30 (0.40) | USP30UCHL1ALDH1A1GPR119TSHR | |
| SCHEMBL14841147 | 0.95 | KMT2A (0.45) | USP30UCHL1ALDH1A1GPR119TSHR | |
| SCHEMBL12333142 | 0.95 | KMT2A (0.45) | USP30UCHL1ALDH1A1GPR119TSHR | |
| SCHEMBL12682635 | 0.95 | NPSR1 (0.44) | USP30UCHL1ALDH1A1GPR119TSHR | |
| SCHEMBL883236 | 0.95 | HTT (0.42) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL10117512 | 0.94 | USP30 (0.40) | USP30UCHL1ALDH1A1GPR119TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| US-8377980-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377980-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011146401-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | USP30 2018/4885UCHL1 2118/4885ALDH1A1 2120/4885 |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885UCHL1 405/4885ALDH1A1 1144/4885 |
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, PYGL | USP30 2512/4885UCHL1 2261/4885ALDH1A1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.